e-ISSN: Pending
Negative / Null Result ReportOpen accessBiochemistry, Genetics and Molecular Biology· cited by 13

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

Guangfu Hu; Guangxia Hu; Chengjiao Zhang; Xiaoyan Lin; Ming Shan; Yanmin Yu; Yongwei Lu; Ruijie Niu · 2020 · BMC Cancer

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: The benefit of adjuvant chemotherapy in invasive lobular carcinoma (ILC) is still unclear. The objective of the current study was to elucidate the effectiveness of adjuvant chemotherapy in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, pT1b-c/N0-1/M0 ILC. METHODS: Based on Surveillance, Epidemiology, and End-Results (SEER) database, we identified original 12,334 HR-positive, HER2-negative, pT1b-c/N0-1/M0 ILC patients, who were then divided into adjuvant chemotherapy group and control group. End-points were overall survival (OS) and breast

Abstract by Guangfu Hu; Guangxia Hu; Chengjiao Zhang; Xiaoyan Lin; Ming Shan; Yanmin Yu; Yongwei Lu; Ruijie Niu, BMC Cancer (2020) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1186/s12885-020-6614-0